LinkGevity
Private Company
Funding information not available
Overview
LinkGevity is a private, preclinical-stage biotech pioneering an AI-driven approach to longevity drug discovery. The company's proprietary 'Blueprint Theory' of aging informs its AI platform, which analyzes biomedical data to map biological triggers and identify novel therapeutic targets. Its lead asset class, Anti-Necrotics™, aims to inhibit necrosis (uncontrolled cell death) and is being advanced into Phase 2 trials for kidney disease and aging, with additional applications in tissue engineering and organ preservation. The company blends deep scientific expertise with a platform designed to systematically generate new drug candidates for healthspan extension.
Technology Platform
AI/ML platform using semantic processing to build 'Blueprint Maps' based on the proprietary Blueprint Theory of aging. It reclassifies biomedical data to identify triggered molecular pathways and novel therapeutic targets for healthspan extension.
Opportunities
Risk Factors
Competitive Landscape
LinkGevity operates in the competitive longevity biotech space, competing with companies developing senolytics (e.g., Unity Biotech), mTOR inhibitors, and other geroprotective mechanisms. Its specific focus on necrosis inhibition is a differentiating angle. In kidney disease, it faces competition from larger pharma but aims to address the root cause (necrosis) where no approved drugs exist.